Challenges in Academic Clinical Research – Interview with Prof. Dr. med. Christoph Schindler
Academic clinical research is indispensable for a medicine that is oriented towards the well-being of patients. However, it faces structural challenges that increasingly make it difficult to carry out. The lack of stable framework conditions makes the efficient conduct of complex trials harder. Regulatory requirements, limited resources, and underfunded infrastructure are among the key obstacles. Prof. Dr. med. Christoph Schindler, Director of the Centre for Clinical Trials (ZKS) at Hannover Medical School (MHH), analyses the challenges from the perspective of academia and outlines approaches for a necessary rethink.
Prof. Schindler, is academic clinical research in Germany currently overshadowed by industrial research?
In Germany, academic clinical research is essential to the healthcare system but structurally disadvantaged. It addresses questions that are decisive for patient care, guidelines, comparator therapies, vulnerable groups and non-commercial innovation. Yet it is precisely this research that suffers from fragmented funding, a heavy regulatory burden and infrastructure that is not funded sustainably. It stands in the shadow of industrial research not because of a lack of relevance but because of weaker framework conditions. Industry, by contrast, has clearly defined business models, a professional trial infrastructure and, in addition, high political visibility. In short: academic clinical research is held back by a mismatch between its benefit to society and the institutional support it receives
If all academic trials disappeared tomorrow, what exactly would be missing?
Academic trials are indispensable. They answer highly relevant questions about patient care for which there is often no viable market incentive. This is exactly what Investigator-Initiated Trials (IITs) aim at, that is, trials initiated by a researcher. Their goal is to gain knowledge. Without academic clinical research, it would not just be “another trial segment” that was missing but the independent part of the system: the part that closes evidence gaps, tests standard therapies against each other, develops off-label options further and improves care under real-world conditions. Medicine would lose its autonomous healthcare intelligence.
What specific roles do KKS and ZKS play in the day-to-day conduct of clinical trials?
KKS/ZKS turn a clinical idea into a trial project that is GCP-compliant, fundable and operationally feasible. They are far more than service units in everyday trial work. KKS/ZKS are the academic “operating platform” for clinical research. They ensure that trials are not only medically meaningful but also regulatorily sound, operationally manageable and scientifically robust. The research organisations support trials from design, budget and application through monitoring, data management and drug safety to analysis, clinical trial report and publication. Without these established structures, many IITs would fail on the practical hurdles between a scientific question and the conduct of the trial.
What are currently the biggest obstacles to academic clinical research?
The biggest limitations can currently be traced back to several structural deficits. First, infrastructure is chronically underfunded. This is made worse by the lack of reliable, long-term funding models. The uncertainty directly affects trial staff: there is a shortage of qualified specialists. Staff who have already been trained are hard to retain under project-based and comparatively poorly paid conditions. In addition, the existing funding logic is too inflexible for modern trials.
Operational processes also remain an obstacle: contract negotiations in Germany still take too long. The standard contractual clauses that have applied since the end of 2025 are meant to speed up processes, but they do not apply to academic, non-commercial trials. Despite extensive digitalisation programmes, the functional bridge to clinical trial infrastructure is still missing. In addition, the culture of trial participation is not sufficiently established in Germany. And last but not least, high regulatory and operational complexity slows down everyday trial work.
Keyword: structural underfunding. Where does it show most clearly in everyday work?
Insufficient structural funding shows in day-to-day operations. There is too little permanent staff because trial funding is tied to projects. Among other things, this makes stable career paths for study coordinators difficult. Budgets are calculated too rigidly. Even normal delays, recruitment problems or design changes put academic trials under financial pressure, because funding has to be fixed in advance on the basis of durations, milestones and spending plans. Many processes still run manually because hospital digitalisation and trial infrastructure do not interlock smoothly, for example in patient screening, feasibility assessments and certain areas of trial documentation. In addition, start-up processes are too slow. Centres have to compensate for this permanently despite insufficient funding.
What might sustainable infrastructure financing look like?
Put simply: a trial may be funded project by project, but the ability to conduct trials in Germany must not be. Academic clinical research should be funded structurally and not only project by project. Sustainable infrastructure funding means permanent base funding for trial centres, separate funding of infrastructure and support costs, and supplementary project funding for the individual trial. A federal-state framework also needs clear quality goals: not “more money somewhere”, but a fundamentally different funding design.
Which specific measures are needed at the political decision-making level to strengthen academic clinical research in Germany sustainably?
Germany is reforming its environment for clinical trials. So far, however, academic clinical research has benefited only in part. To unfold its full potential, IITs must be systematically taken into account, and trial centres must be funded as high-performing research infrastructures. This is a key lever that we will continue to pursue consistently.